Core Insights - Novo Nordisk has launched a subscription program for its Wegovy obesity drug, aimed at providing cash-paying patients with lower and more predictable monthly prices [1][2] Subscription Program Details - Eligible patients can select from three, six, or twelve-month subscription plans for the Wegovy injection or the two highest doses of the newly launched pill, with longer plans offering reduced monthly costs [2] - The company anticipates that patients could save up to $1,200 annually on the injection and up to $600 on the pill compared to paying for individual doses each month [2] - Patients will benefit from flat monthly prices even if they switch to different doses during the subscription period [3] Market Positioning and Patient Support - This subscription model is described as a unique opportunity to assist patients in both initiating and maintaining their therapy, addressing pricing fluctuations [4] - The program is expected to be available through several telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame, and Hims & Hers, with plans for additional partners in the future [3] Challenges in Treatment Adherence - A significant challenge in the use of GLP-1 medications, such as Wegovy, is the difficulty patients face in maintaining treatment, with a study indicating that approximately 65% of patients with obesity discontinue treatment within a year due to various factors [5]

Core Insights - The med-spa and cash-pay healthcare sector is experiencing significant growth, with a surge in the number of clinics and practices offering direct access to physicians for a membership fee [2][8] - VITL, a startup focused on e-prescribing solutions for cash-pay medical businesses, has raised $7.5 million in Series A funding to address inefficiencies in prescription management [3][9] Group 1: VITL's Solution and Impact - VITL's e-prescribing platform connects clinics to a nationwide network of compounding pharmacies, enabling real-time price comparisons and order tracking, thus streamlining the prescription process [4][10] - The platform significantly reduces prescription processing time from several minutes to a few seconds, leading to substantial time savings for clinics [5][6] - VITL estimates that its technology can save clients up to two full workdays per month, demonstrating its value to cash-pay providers [7] Group 2: Market Potential and Competition - VITL has onboarded over 630 clinics within a year of its launch, generating annualized recurring revenue (ARR) projected to exceed $10 million, indicating strong market demand [7] - The cash-pay healthcare market is vast, with tens of thousands of clinics, and is expected to grow as interest in cash-pay treatments like GLP-1 drugs and aesthetic procedures increases [8] - VITL differentiates itself from competitors like Surescripts and Jane Software by focusing exclusively on the workflow needs of the cash-pay medical sector [10]

Core Insights - Lexaria Bioscience Corp. is focusing on developing oral GLP-1 drug delivery systems in response to patient preferences for safer and better-tolerated options compared to injected alternatives [2][6][16] Industry Overview - The GLP-1 drug market is experiencing significant growth, with Eli Lilly's tirzepatide projected to be the top-selling drug in 2026, generating approximately $45 billion in revenue, while Novo Nordisk's semaglutide is expected to generate nearly $40 billion [3] - Analysts have raised revenue forecasts for the GLP-1 market, with projections of $139 billion by 2030 from TD Cowen and $180 billion by 2035 from Roots Analysis [3] Patient Experience and Market Needs - A large percentage of patients using GLP-1 drugs experience gastrointestinal side effects, with 74% of injected semaglutide users and 80% of oral semaglutide users reporting such issues [4] - A study indicated that 46.5% of patients with type 2 diabetes and 64.8% without it discontinued GLP-1 drug use within one year, highlighting the need for improved patient experiences [5] Strategic Developments - Lexaria is enhancing its DehydraTECH GLP-1 platform to improve oral delivery and reduce side effects, aiming to establish partnerships with leading pharmaceutical companies [2][17] - The company is in early-stage discussions with several multinational pharmaceutical firms to leverage its patented technology in the GLP-1 market [17] Market Potential - The oral GLP-1 market is anticipated to grow significantly, with forecasts suggesting it could represent a $40 billion to $45 billion annual market within four years [15] - Novo Nordisk's oral GLP-1 tablets are expected to capture over 33% of the GLP-1 market by 2030, up from less than 5% in 2025 [14] Competitive Landscape - Pfizer's orally-delivered GLP-1 candidate, danuglipron, was discontinued due to safety concerns, indicating the challenges in developing new oral alternatives [10] - Eli Lilly is developing orforglipron, which has shown promising results in weight loss studies but also higher rates of adverse side effects compared to semaglutide [13][14]

Core Insights - Danone is set to acquire Huel, a company specializing in vegan, powdered meal replacements, for approximately 1 billion euros ($1.15 billion) as consumer preferences shift towards healthier and environmentally sustainable options [1][3] - The acquisition aims to combine Huel's product range and digital capabilities with Danone's global reach and nutritional expertise, targeting the growing market for nutritionally complete meals [2] Group 1: Company Overview - Huel offers a variety of protein shakes and drinks that are fortified with essential nutrients, appealing to a health-conscious demographic [2] - The brand has gained celebrity endorsements, including from Steven Bartlett and Idris Elba, enhancing its market visibility [2] Group 2: Strategic Rationale - Danone's CEO highlighted that the acquisition aligns with the company's portfolio, which includes yoghurts and water, and is complementary to the increasing health awareness and the rise of GLP-1 drugs [4] - The deal is seen as an opportunity to tap into the fast-growing market for complete nutritional solutions, addressing the common issue of inadequate protein, fiber, and nutrient intake among consumers [3]

Core Viewpoint - Novo Nordisk has faced significant challenges in the past year, including a CEO change, a halved share price, and reduced guidance due to increased competition in the GLP-1 drug market [1][5] Company Performance - The stock has seen a drastic decline, leading to a bearish sentiment among investors and analysts downgrading price targets [5] - Despite these challenges, Novo Nordisk remains a strong healthcare business with high margins and a solid product portfolio [6] Product Development - Novo Nordisk is developing a promising GLP-1 drug, UBT251, in collaboration with The United Laboratories International Holdings Limited, which showed an average weight loss of 19.7% after 24 weeks in a phase 2 trial [3] - The company is competing with Eli Lilly, which has a rival triple agonist drug, retatrutide, that achieved an average weight loss of 28.7% after 68 weeks [4] Investment Potential - The stock is currently trading at 11 times its trailing earnings, significantly lower than the S&P 500 average of 24, suggesting potential value for long-term investors [7] - There is optimism that if UBT251 can demonstrate effectiveness over a longer duration, it could enhance growth prospects for Novo Nordisk in the GLP-1 market [4]

Core Insights - Artisan Small Cap Fund reported strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index despite elevated volatility and shifting market sentiment influenced by various political and economic factors [1] Group 1: Fund Performance - The Fund seeks to invest in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1] - In Q4 2025, the market leadership shifted back to companies with durable profit cycles, while the Fund's full-year performance trailed both indexes [1] Group 2: Stevanato Group S.p.A. Analysis - Stevanato Group S.p.A. (NYSE:STVN) is highlighted as a key holding, providing specialty glass and plastic packaging to the healthcare industry [2][3] - As of March 16, 2026, Stevanato Group's stock closed at $15.35 per share, with a one-month return of -3.82% and a 12-month return of 29.46% [2] - The stock faced challenges due to market concerns regarding Eli Lilly's pending launch of an oral GLP-1, impacting Stevanato's profit cycle related to vial and syringe production [3] - Despite the challenges, the company remains a focus for investment due to anticipated growth in liquid-based biological drugs and increased drug volume from Medicare and Medicaid coverage of GLP-1s [3]

Core Viewpoint - The relationship between pharmaceutical giant Novo Nordisk and telehealth company Hims & Hers Health has evolved from collaboration to legal disputes, but a new agreement allows Hims & Hers to sell Novo Nordisk's GLP-1 drugs, which could benefit both companies and their investors [1][2]. Group 1: Agreement Details - Hims & Hers Health will now sell FDA-approved GLP-1 drugs, Ozempic and Wegovy, including the newly approved Wegovy pill, improving its market position [5]. - Previously, Hims & Hers was selling compounded versions of these drugs, which were not FDA-approved, posing a risk to its growth potential amid increasing demand for GLP-1 drugs [5]. Group 2: Company Performance - Novo Nordisk has reduced its sales guidance for the upcoming year due to competition, particularly from Eli Lilly's GLP-1 treatments and the trend of patients opting for compounded versions to save costs [6]. - The new agreement with Hims & Hers Health could enhance Novo Nordisk's growth rate moving forward [6]. Group 3: Stock Performance - Both Novo Nordisk and Hims & Hers Health have seen their stock prices decline over 20% this year, with Hims & Hers experiencing more volatility, including a drop of up to 55% at one point [7]. - Novo Nordisk, valued at nearly $170 billion, is considered a safer investment compared to Hims & Hers, which has a market cap of around $6 billion and lighter margins [7][8].

Core Viewpoint - Hims & Hers has transitioned from compounded GLP-1 drugs to selling branded Wegovy and Ozempic directly, resolving legal issues and restoring investor confidence, leading to a significant stock price rebound of 64% since the announcement [1][2] Group 1: Company Developments - Hims & Hers agreed to sell branded Wegovy and Ozempic while discontinuing most compounded GLP-1 advertising, resolving a patent lawsuit with Novo Nordisk [1] - The company had seen its shares drop over 75% due to regulatory scrutiny and legal challenges but has now regained legitimacy with the new distribution rights [1] - The pivot to branded products enhances Hims' credibility as a healthcare partner and removes concerns about counterfeit safety and patent violations [1] Group 2: Market Response - Following the announcement, Hims' stock surged by 64%, including a remarkable 40% gain in a single day [1] - Analysts have responded positively, with Needham upgrading its rating to Buy with a target price of $30, while other firms have raised their price targets [1] - Revenue projections for Hims are robust, with expectations of $2.35 billion in 2025, reflecting a 59% year-over-year increase [1] Group 3: Risks and Challenges - Despite the positive developments, Hims is now heavily reliant on Novo Nordisk as a single supplier for its growth, which poses risks if production issues arise or if Novo changes its strategy [1][2] - The stock's current valuation is high, and analysts caution that any issues with patient retention or slower adoption of branded products could negatively impact share prices [1] - Historical context shows that previous collaborations with Novo have faced challenges, raising concerns about the sustainability of the current partnership [1]

Company Overview - Hims & Hers Health (HIMS) reported full-year revenue of $2.347 billion, a 59% increase year-over-year, with a subscriber base exceeding 2.5 million and monthly revenue per subscriber at $83 [1][2] - Progyny (PGNY) achieved full-year revenue of $1.289 billion, up 10.4% year-over-year, with record adjusted EBITDA of $222.09 million and no debt [1][2] Analyst Ratings and Price Targets - Barclays raised the price target for Hims & Hers to $29 from $25, maintaining an Overweight rating, following a distribution agreement with Novo Nordisk that alleviated legal concerns [1][2] - Canaccord reduced Progyny's price target to $19 from $26 while keeping a Hold rating, citing cautious guidance for 2026 [1][2] Market Reactions and Performance - Hims & Hers shares surged 48.36% in the week ending March 10 after the Novo deal announcement, with an additional 5.91% increase on the most recent trading day [1][2] - Progyny's shares fell 30.26% year-to-date, trading at $17.91, just above a 52-week low, following weak 2026 guidance [1][2] Growth Projections - Hims & Hers projects 2026 revenue between $2.7 billion and $2.9 billion, with adjusted EBITDA expected to be between $300 million and $375 million [2] - Progyny's 2026 revenue guidance is between $1.355 billion and $1.405 billion, indicating a growth rate of only 5.1% to 9.0%, a significant slowdown from 2025 [2] Strategic Developments - The Novo Nordisk agreement allows Hims to distribute approved Ozempic and Wegovy injectables, which is expected to enhance growth opportunities [1][2] - The departure of Progyny's president at the end of 2025 is a leadership change that investors are monitoring closely [2]

Core Insights - Wall Street analysts have turned bullish on Hims & Hers (HIMS), Teladoc Health (TDOC), and Alector (ALEC) due to strategic partnerships that have reshaped their risk profiles [1][2] Company Summaries Hims & Hers Health (HIMS) - HIMS stock surged 34.47% to $22.16 after resolving a lawsuit with Novo Nordisk through a distribution partnership, with price targets set between $23 and $28 by analysts [1] - BofA upgraded HIMS from Underperform to Neutral, raising the price target from $12.50 to $23, citing the removal of legal risks [1] - Deutsche Bank maintained a Hold rating but increased the target to $28, highlighting the strategic shift away from compounded semaglutide [1][2] Teladoc Health (TDOC) - TDOC's stock is currently priced at $5.30, with Deutsche Bank upgrading it from Hold to Buy and setting a price target of $11, indicating substantial upside potential [1] - The upgrade is based on compelling valuation, a credible turnaround plan for the BetterHelp segment, and stable revenue from the Integrated Care segment, which grew 2% in Q3 2025 [1][2] - The company reported Q3 2025 revenue of $626.44 million, missing consensus estimates, with BetterHelp revenue declining 8% [1] Alector (ALEC) - ALEC's stock rose 40.38% year-to-date to $2.19, with BTIG upgrading it from Neutral to Buy and setting a price target of $6 [1] - The upgrade reflects confidence in Alector's pivot to its Alector Brain Carrier (ABC) platform following a setback in a frontotemporal dementia trial [1] - Alector reported Q4 2025 revenue of $6.24 million, significantly beating the consensus estimate of $2.11 million, and holds $256 million in cash to fund operations through 2027 [1][2]